Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors

Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors

Global hemostatic assays including thromboelastography (TEG), Innovance ETP (endogenous thrombin potential), and Thrombinoscope could measure thrombin generation potential and be useful to guide management of patients with factor VIII (FVIII) inhibitors. However, the performance characteristics of t...

Full description

Bibliographic Details
Main Authors:	Ping Chen MD, PhD, Jayesh Jani MS, Michael B. Streiff MD, Gang Zheng MD, PhD, Thomas S. Kickler MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-03-01
Series:	Clinical and Applied Thrombosis/Hemostasis
Online Access:	https://doi.org/10.1177/1076029619836171

Similar Items

The Evaluation of Hemostatic Abnormalities Using a CWA-Small Amount Tissue Factor Induced FIX Activation Assay in Major Orthopedic Surgery Patients
by: Masahiro Hasegawa MD, PhD, et al.
Published: (2021-05-01)

Comments to: An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia by APTT Waveform, Peak Heights of APTT Waveform Are Useful for Diagnosing Hemophilia or Inhibitor
by: Takeshi Matsumoto MD, PhD, et al.
Published: (2019-01-01)

Pulley traction–assisted endoscopic submucosal dissection with hemostatic forceps for a laterally spreading tumor in the ascending colon
by: Satoki Shichijo, MD, PhD, et al.
Published: (2020-12-01)

Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
by: Jerzy Windyga MD, PhD, et al.
Published: (2020-08-01)

Safety and Hemostatic Effectiveness of SURGICEL® Powder in Mild and Moderate Intraoperative Bleeding
by: Nawwar Al-Attar FRCS, FETCS, PhD, et al.
Published: (2023-07-01)

Plasma Levels of Vascular Endothelial Growth Factor and Selected Hemostatic Parameters in Association With Treatment Response in Multiple Myeloma
by: Juraj Sokol MD, PhD, et al.
Published: (2019-02-01)

Device-Induced Hemostatic Disorders in Mechanically Assisted Circulation
by: Shigang Wang MD, et al.
Published: (2021-02-01)

Hemostatic powder facts
by: David R. Wagner, MS, et al.
Published: (2019-04-01)

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
by: Yuki Hatayama PhD, et al.
Published: (2022-02-01)

Hemostatic forceps used as a scissor-type knife in combination with the transanal-traction method for assisted endoscopic submucosal dissection in the area of the dentate line
by: Felipe Ramos-Zabala, MD, PhD, et al.
Published: (2021-01-01)

Upregulation of Coagulation Factor VIII and Fibrinogen After Pulmonary Endarterectomy in Patients with Chronic Thromboembolic Pulmonary Hypertension
by: Lasse Myllylahti MD, et al.
Published: (2023-03-01)

Efficacy and Safety of Bioabsorbable Bone Hemostatic Agent in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial
by: Jong-Keun Kim MD, et al.
Published: (2021-06-01)

Hemostatic powder: a new ally in the management of postsphincterotomy bleeding
by: Felipe Iankelevich Baracat, MD, et al.
Published: (2017-11-01)

Alternative approach to hemostatic particle spraying for treatment of GI bleeding by the use of cross-platform devices
by: Abdul Haseeb, MD, et al.
Published: (2019-08-01)

Clinical Efficacy of a Kaolin-impregnated Dressing for Hemostatic Control in Diabetic Foot Ulcer Patients Receiving Anticoagulant Therapy in an Outpatient Clinic
by: Yeokgu Hwang MD, et al.
Published: (2017-09-01)

Viscoelastic hemostatic assays
by: Anil Sachdev, et al.
Published: (2015-01-01)

COVID-19 vaccine-induced Recurrence of the Radiation Recall Phenomenon in the Laryngeal Mucosa Due to a VEGF Inhibitor
by: Shotaro Tatekawa, MD, PhD, et al.
Published: (2022-11-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
by: Hideo Oishi, MD, et al.
Published: (2020-10-01)

Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
by: Felicio Savioli MD, MSc, et al.
Published: (2022-03-01)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
by: Matilde Kanstrup Andersen BA, et al.
Published: (2023-09-01)

Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A
by: Aveen M. Raouf Abdulqader MD, PhD, et al.
Published: (2020-01-01)

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
by: Ryota Nakamura, MD, et al.
Published: (2023-06-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
by: Tatsuya Nishikawa, MD, PhD, et al.
Published: (2022-07-01)

Effect of Age on the Hemostatic Function in Patients with Degenerative Diseases of the Large Joints
by: Igor L. Shlykov, PhD¹, ScD¹, et al.
Published: (2013-06-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
by: Daisuke Hazama, MD, PhD, et al.
Published: (2024-01-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
by: Yasunori Murata, MD, PhD, et al.
Published: (2023-12-01)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
by: Tianyu Wu MD, et al.
Published: (2021-02-01)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
by: Whitney E. Lewis, PharmD, et al.
Published: (2021-11-01)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
by: Hitomi Jo, MD, PhD, et al.
Published: (2023-04-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Administration of a TLR9 Inhibitor Attenuates the Development and Progression of Heart Failure in Mice
by: Hiromichi Ueda, MD, et al.
Published: (2019-06-01)

Aromatase inhibitor for the treatment of primary mucinous carcinoma of the skin with distant metastasis
by: Hideaki Miyachi, MD, PhD, et al.
Published: (2018-04-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay
by: Hideo Wada MD, PhD, et al.
Published: (2021-02-01)

MPs-ACT, an Assay to Evaluate the Procoagulant Activity of Microparticles
by: Yalong Gao PhD, et al.
Published: (2023-02-01)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
by: Tomoya Sawada, MD, et al.
Published: (2023-06-01)

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema
by: Inmaculada Martinez-Saguer, MD, PhD, et al.
Published: (2024-02-01)

The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation
by: Seiichiro Tada, MD, et al.
Published: (2020-09-01)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01)